Intravenous Immunoglobulin Industry Outlook 2025-2029: Market Set to Cross $21.53 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Intravenous Immunoglobulin Market Size By 2025?
In recent times, the intravenous immunoglobulin market has exhibited substantial growth. The market size is predicted to rise from $14.66 billion in 2024 to $15.57 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The increase experienced in the historical period can be credited to the use of immunoglobulins in treating primary immunodeficiency disorders, managing neurological conditions, a growing elderly population, technology advancements in plasma fractionation techniques, enlargement of indications in neurology and treatments of infectious diseases as well as pediatric immunodeficiency.

How Big Is the Intravenous Immunoglobulin Market Size Expected to Grow by 2029?
The market for intravenous immunoglobulin is anticipated to expand significantly in the upcoming years, with a projected growth up to "$21.53 billion by 2029, experiencing a CAGR of 8.4%. The expansion during the forecast period is largely due to the rising prevalence of autoimmune disorders, continuous research in the field of immunology, increased healare spending, surge in cancer cases, and the introduction of innovative immunoglobulin products and personalized medicine treatments. Future trends forecasting this growth include the treatment of primary immunodeficiency disorders (PIDD), quick technological advancements, strategic alliances and partnerships, improved manufacturing techniques, application in neurology, utilization in hematology, and progress in immunotherapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Key Market Drivers Powering Intravenous Immunoglobulin Market Expansion and Growth?
The anticipated growth of the intravenous immunoglobulin market can be attributed to the rising older adult population. This demographic refers to those aged 65 and above. As individuals age, their immune functions decline and there is a reduced presence of antibodies. Consequently, they require immunoglobulins to replenish their antibody levels. This leads to a growing demand for intravenous immunoglobulins, thereby propelling the intravenous immunoglobulin market. According to the Population Reference Bureau, a nonprofit organization based in Kenya, the American population aged 65 and older is projected to escalate from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Furthermore, this age group's percentage of the entire population is expected to increase from 17% to 23% during the same timeframe. Hence, the surging older adult population will facilitate the progression of the intravenous immunoglobulin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Which Emerging Trends Are Transforming the Intravenous Immunoglobulin Market in 2025?
Trending prominently in the intravenous immunoglobulin market is product innovation, as leading firms concentrate on creating innovative products like liquid immune globulin formulations to treat immunodeficiency diseases and maintain their market dominance. One example of this is GC Pharma, a South Korean pharmaceutical firm that in December 2023 launched Alyglo, a product approved by the US Food and Drug Administration (FDA). Alyglo presents as a sterile, ready-to-use liquid formulation with 10% immunoglobulin G (IgG), delivering 100 mg/mL of protein, with no less than 96% of it being human IgG derived from combined human plasma. It is particularly prescribed for adults who are at least 17 years old and suffering from primary humoral immunodeficiency (PI). Conditions encompass congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

What Are the Emerging Segments in the Intravenous Immunoglobulin Market?
The intravenous immunoglobulin market covered in this report is segmented -

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care

Subsegments:
1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG
2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM
3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA
4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE
5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Who Are the Global Leaders in the Intravenous Immunoglobulin Market?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Which are the Top Profitable Regional Markets for the Intravenous Immunoglobulin Industry?
North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.